Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Consun Pharmaceutical Group's average EPS without NRIGrowth Rate was 20.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 13.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 12.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 17.60% per year.
During the past 13 years, Consun Pharmaceutical Group's highest 3-Year average EPS without NRI Growth Rate was 148.10% per year. The lowest was -44.10% per year. And the median was 13.50% per year.
Consun Pharmaceutical Group (OTCPK:CPHGF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Consun Pharmaceutical Group Earnings per Share (Diluted) Related Terms
Consun Pharmaceutical Group Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Earnings per Share (Diluted) Chart
CPHGF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's PE Ratio distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's PE Ratio falls into.
Consun Pharmaceutical Group Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Consun Pharmaceutical Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.18 mean?
Consun Pharmaceutical Group (CPHGF) has a Earnings per Share (Diluted) of $0.18 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Consun Pharmaceutical Group and its competitors. According to the industry distribution chart, Consun Pharmaceutical Group ranks #334 out of 785 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Consun Pharmaceutical Group's Earnings per Share (Diluted) too high?
Consun Pharmaceutical Group's current Earnings per Share (Diluted) is $0.18. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.70. Consun Pharmaceutical Group's value of $0.18 is 98.1% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #334 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #334 out of 785 companies for Earnings per Share (Diluted). This puts Consun Pharmaceutical Group in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.70. Consun Pharmaceutical Group's value of $0.18 is 98.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Earnings per Share (Diluted) of $0.18 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Earnings per Share (Diluted) is $0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.80 — trading 195.1% above its estimated fair value. The current Earnings per Share (Diluted) is $0.18 and 98.1% below the Drug Manufacturers industry median of 9.70. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Earnings per Share (Diluted) is $0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 195.1% above its estimated GF Value™ of $0.61.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Earnings per Share (Diluted): $0.18
GF Value™: $0.61 vs. price of $1.80 (195.1% above fair value)
Industry Position: 98.1% below the Drug Manufacturers median (#334 of 785)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
